Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 4, pp 200–200 | Cite as

Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”

  • Katherine A. Lyseng-WilliamsonEmail author
Open Access
Correction
  • 167 Downloads

Correction to: Drugs & Therapy Perspectives  https://doi.org/10.1007/s40267-018-00596-3

Paragraph 1, Sentences 1 and 2: the following text, which previously read:

“After publication in volume 34, issue 10, pages 457–465, Ipsen Pharma requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ipsen Pharma.”

Should read:

“After publication in volume 34, issue 10, pages 457–465, Exelixis, Inc. (Alameda, CA, USA) requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Exelixis, Inc. (Alameda, CA, USA).”

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations